Summit Therapeutics (SMMT) Stock
Biotech company developing new treatments for patients. Here's the price, business snapshot, and what's worth knowing about Summit Therapeutics in June 2026.
Summit Therapeutics Inc (ticker: SMMT) is a biotechnology company focused on developing novel therapeutics. With a market capitalisation of about $13.95 billion, the company attracts attention due to its research-led profile and potential upside from clinical development milestones. Investors should know Summit typically spends heavily on research and development and may have little or no recurring revenue until products reach the market. That creates a binary investment profile: positive clinical trial results or regulatory approvals can materially re-rate the stock, while setbacks can depress the share price. Key considerations include cash runway, partnership or licensing deals, the stage of clinical programmes, and regulatory timelines. Biotech shares can be volatile and speculative; they suit investors who can tolerate high risk and long horizons. This summary is educational, not personalised financial advice — values can rise and fall and outcomes are uncertain.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Summit Therapeutics stock, anticipating it could rise to $24.6.
Financial Health
Summit Therapeutics is showing promising cash flow and book value, indicating solid financial management.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring SMMT
UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and regulatory decisions can drive major moves in the share price, though outcomes are uncertain and can be binary.
Growth vs Risk
Potential for material upside if therapies advance, balanced by high cash burn, financing needs and sector volatility.
Partnerships Matter
Collaborations or licensing deals can de‑risk programmes or provide funding, but terms and execution affect value and are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
